Coronavirus and Atopic Dermatitis (AD) / Alopecia Reporting Database

Questions remain regarding how the COVID-19 pandemic impacts patients with atopic dermatitis (AD) or alopecia. It is not known what effect systemic medications have on COVID-19 outcomes and whether COVID-19 vaccinations impact on existing skin diseases.

To investigate this, we have created a number of secure, online, de-identified Personal Health Identifier (PHI) – free reporting registries, and an anonymous patient reported survey.

Physicians
We encourage physicians worldwide to report ALL cases of COVID-19 in their atopic dermatitis and alopecia patients treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). Please follow the links below to register by clicking on either of the physician entered registry logos.

Patients with atopic dermatitis
The patient survey is for people with eczema (atopic dermatitis, atopic eczema) and asks questions about their experiences during the COVID-19 pandemic, their treatments for eczema and about COVID-19 vaccinations. This will help us better understand how COVID-19 affects people with eczema and how to improve their care. If you are a patient with eczema we encourage you to complete the anonymous survey by clicking on the green SECURE-AD Patients survey logo below.

Thank you in advance for your participation.

We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia patients treated with systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).
We encourage clinicians worldwide to report ALL cases of COVID-19 in their AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).
The SECURE-AD Patient survey allows patients with atopic dermatitis (atopic eczema) to report their experiences during the COVID-19 pandemic. We are interested in those who suffered from COVID-19 infection as well as those who did not, and we will investigate how COVID-19 vaccination impacts on patients with atopic dermatitis.

SECURE-AD update: current data

We are incredibly grateful for your ongoing contributions to the international atopic dermatitis and COVID-19 reporting registries. We recently analysed the early results of patients with atopic dermatitis who developed COVID-19. There are currently 391 cases reported in the SECURE-AD Registry. To date, 726 patients registered themselves in the SECURE-AD Patient Survey, of whom 291 contracted COVID-19. You can find the first results below (analysed data of 204 and 187 patients respectively).

Please use the following citation if referencing the data on this page: Alan Irvine, Carsten Flohr, Phyllis Spuls, Angela Bosma, Conor Broderick, Ching-Chi Chi, Aaron Drucker, Kenji Kabashima, Annelie Musters, David Prieto-Merino, Dmitri Wall, Bernd Arents, Tim Burton. SECURE-AD Database Public Data Update. www.secure-derm.com. Accessed on MM/DD/YY.


We are using cookies on our website

Please confirm, if you accept our tracking cookies. You can also decline the tracking, so you can continue to visit our website without any data sent to third party services.